Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3b comparison of guselkumab versus fumaric acid esters in systemic-naive moderate to severe plaque psoriasis
2016-002135-15Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Sep 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of guselkumab in plaque psoriasis and psoriasis (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: PASI 90 response at Week 24. Started Sep 2016; status: completed.
02
Drugs
guselkumab
03
Conditions
plaque psoriasispsoriasis
Beyond the preview
Go deeper on 2016-002135-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-002135-15.